Cristina Magi‐Galluzzi

Author

Also Known As

C Magi-Galluzzi, C. Magi-Galluzzi, CRISTINA MAGI-GALLUZZI, Cristina Magi-Galluzzi, Cristina Magi‐Galluzzi, Ehdaie, Behfar, Laurence A Galea, Magi-Galluzzi, Cristina, Przybycin, Christopher G, Verkarre, Virginie

477

Publications

19.1K

Citations

H-Index

116

Concepts

All Affiliations

Cleveland Clinic University of Alabama at Birmingham Cleveland Clinic Lerner College of Medicine University of Calgary University of Michigan

About

Cristina Magi‐Galluzzi is an author at Cleveland Clinic specializing in medicine, urology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	51	90	11.1K
2	Engineering	5	5	386
3	Health Sciences	5	5	215
4	Natural Sciences	2	2	910
5	Public Health	1	1	30

Cristina Magi‐Galluzzi

171

Publications

16.9K

Citations

H-Index

Page 1

	Year	Citations
A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score Jonathan I. Epstein, Michael J. Zeléfsky, Daniel D. Sjoberg, European Urology UrologyGenitourinary CancerMedicineComputational PathologyValidated Alternative	2015	1.3K
EZH2 Oncogenic Activity in Castration-Resistant Prostate Cancer Cells Is Polycomb-Independent Kexin Xu, Zhenhua J. Wu, Anna C. Groner, Science Histone ModificationsEpigenetic ChangeCancer BiologyEpigeneticsTumor Biology	2012	873
The International Society of Urological Pathology (ISUP) Grading System for Renal Cell Carcinoma and Other Prognostic Parameters Brett Delahunt, John C. Cheville, Guido Martignoni, The American Journal of Surgical Pathology Surgical OncologyRenal PathologyPathologyCarcinomaRenal Function	2013	839
A 17-gene Assay to Predict Prostate Cancer Aggressiveness in the Context of Gleason Grade Heterogeneity, Tumor Multifocality, and Biopsy Undersampling Eric A. Klein, Matthew R. Cooperberg, Cristina Magi‐Galluzzi, European Urology Gleason Grade HeterogeneityUrologyOncologyGenitourinary CancerTumor Heterogeneity	2014	650
Identification of a Novel Gammaretrovirus in Prostate Tumors of Patients Homozygous for R462Q RNASEL Variant Anatoly Urisman, Ross J. Molinaro, Nicole Fischer, PLoS Pathogens R462q Rnasel VariantRnase LUrologyViral ReplicationMolecular Virology	2006	560
The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas. P. Tan, Blake Cady, Molly Wanner, PubMed Surgical OncologyBreast OncologyLow P27Cancer ManagementPathology	1997	354
Succinate Dehydrogenase (SDH)-deficient Renal Carcinoma Anthony J. Gill, Ondřej Hes, Thomas Papathomas, The American Journal of Surgical Pathology Succinate DehydrogenaseUrologyTumoral PathologyGenitourinary CancerKidney Research	2014	330
Analytical validation of the Oncotype DX prostate cancer assay – a clinical RT-PCR assay optimized for prostate needle biopsies Dejan Knezevic, Audrey D. Goddard, Nisha Natraj, BMC Genomics	2013	323
Tuberous Sclerosis–associated Renal Cell Carcinoma Juan Guo, Maria Tretiakova, Megan L. Troxell, The American Journal of Surgical Pathology Tuberous Sclerosis ComplexUrologyGenitourinary CancerRenal PathologySurgical Pathology	2014	289
<i>TMPRSS2–ERG</i> gene fusion prevalence and class are significantly different in prostate cancer of caucasian, african‐american and japanese patients Cristina Magi‐Galluzzi, Toyonori Tsusuki, Paul Elson, The Prostate	2010	271

Page 1